Gilead Sciences (GILD) Misses Q1 EPS by 5c; Reiterates Full Year 2017 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Bullish Options Activity in Gilead Sciences (GILD) Post Earnings Announcement -Susquehanna
May 3, 2017 2:46 PM EDTSusquehanna options strategists Alison Edwards notes bullish options activity in Gilead Sciences (NASDAQ: GILD), following the company's earnings announcement, as an opening investor bought ~10,000 Dec 70 Calls for $3.30 creating ~400,000 shares to buy.
... MoreGilead Sciences (GILD) PT Raised to $76 at BMO Capital Following 1Q
May 3, 2017 9:17 AM EDTBMO Capital raised its price target on Gilead Sciences (NASDAQ: GILD) to $76.00 (from $75.00) while maintaining a Market Perform rating. GILD reported 1Q revenues of $6.5bn, below the Street's estimates of $6.62bn, as continued strength from HIV could not off-set further deterioration in HCV.
GILD... More
